Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Crystalline and co-crystal polymorph structures: MerckRecent Research Landscape

Unstable molecular packing leads to inconsistent bioavailability and poor shelf-life in complex inhibitors. These innovations engineer specific crystalline lattices and boronic acid adducts to ensure thermodynamic stability and manufacturing reproducibility.

What technical problems is Merck addressing in Crystalline and co-crystal polymorph structures?

Poor solid state stability

(9)evidences

Amorphous or unstable crystalline phases lead to unpredictable drug degradation and inconsistent shelf life. Establishing stable crystalline or co-crystal forms ensures chemical and physical integrity during storage.

Poor drug bioavailability

(5)evidences

Low solubility and variable dissolution rates in crystalline drug forms limit therapeutic efficacy. Improving these properties ensures consistent systemic absorption and predictable clinical performance.